evipedia.ai
← Back

Dong Quai for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Angelica sinensis, Dang Gui, Danggui, Dang Quai, Tang Kuei, Chinese Angelica Root, Radix Angelicae Sinensis, Female Ginseng

Motivation

Dong quai is the dried root of a tall flowering plant in the carrot family that grows in the cool mountain regions of China, Japan, and Korea. It has been prepared as both food and medicine for roughly two thousand years, most often simmered in soups, steeped in wine, or boiled together with other roots in a shared pot rather than swallowed on its own. Modern supplement shelves present it very differently: as a single-ingredient extract sold for women’s hormonal health, circulation, and energy.

That shift from shared kitchen ingredient to solo capsule sits at the center of the argument about it. Traditional practice almost never used the root by itself, so the small number of Western trials that tested it alone tested a preparation that traditional practitioners would not recognize. The root carries compounds that discourage blood clotting alongside compounds that faintly imitate the body’s own estrogen, which means its promise and its cautions grow from the same chemistry.

This review examines what human and laboratory work shows about dong quai’s effects on menstrual pain, menopausal symptoms, and blood building, where its risks lie, and how the single-herb and multi-herb forms differ.

Benefits - Risks - Protocol - Conclusion

High-level sources that discuss dong quai by name in substantial depth, selected for their usefulness in understanding the whole intervention rather than a single outcome.

Note on priority sources: of the six priority expert platforms, only Life Extension carries substantive dong quai content, included above. Site searches and domain-restricted web searches of the other five returned unrelated results, so peer-reviewed narrative reviews and expert clinical commentary fill the remaining places.

Grokipedia

  • Angelica sinensis

    Grokipedia files the herb under its botanical name and covers taxonomy, cultivation regions, constituent chemistry and traditional indications, giving a fast orientation before the clinical literature is approached.

Examine

  • Dong Quai

    Examine’s page is short and carries an important caveat: its summary text describes Angelica gigas, the Korean species, rather than Angelica sinensis, and its research breakdown has been archived.

ConsumerLab

Systematic Reviews

Pooled analyses that bear on dong quai, its principal constituent, or the classical formulas in which the root is the named lead herb.

Note on coverage: systematic reviews exist for the claimed effects below, but none exists for the principal countervailing risk — potentiation of anticoagulant (clot-slowing) and antiplatelet (platelet-clumping-blocking) drugs — which is represented in the literature only by narrative interaction reviews and case reports. That side of the trade-off is unrepresented at this evidence level. Note also that almost all of the pooled trials were conducted and published by traditional Chinese medicine institutions, whose academic and commercial standing is tied to positive findings; this conflict of interest is revisited in the Conclusion.

Mechanism of Action

Dong quai’s activity is spread across three chemically unrelated fractions rather than concentrated in one molecule.

The volatile oil is dominated by phthalides (a family of small aromatic ring compounds), chiefly Z-ligustilide, which relax smooth muscle, widen blood vessels, and in animal models limit inflammatory and oxidative injury in brain tissue. Ligustilide is fat-soluble, chemically unstable, and heavily cleared on its first pass through the liver, so blood levels after swallowing are low and short-lived — in rodents the half-life is on the order of tens of minutes. The phenolic acid fraction is led by ferulic acid, a modest antioxidant that also dampens platelet clumping and thromboxane formation (thromboxane is a clot-promoting signal released by platelets); it is absorbed within an hour, attached to sugar or sulfate groups in the gut wall and liver, and cleared within a few hours. The polysaccharide fraction is not absorbed intact. It acts locally on gut-associated immune cells, prompting release of interleukin-6 (an immune signalling protein) and granulocyte-macrophage colony-stimulating factor (a growth signal that drives blood cell production), the proposed basis for the root’s blood-building reputation.

A second mechanism is contested. Cell and ovariectomized-rat (ovaries surgically removed) work shows weak estrogen-receptor activation, yet the one controlled human trial found no change in womb lining thickness or vaginal cell maturation, leaving estrogen signalling at human doses unresolved. Coumarins in the root also weakly inhibit CYP drug-metabolizing enzymes (the liver’s main drug-clearing family), the plausible route to its warfarin interaction.

Historical Context & Evolution

Dong quai enters the written record in the Shennong Bencao Jing, the Han-dynasty herbal compiled around the first to second century, where the root is classed as a blood-supplementing agent. Its original use was not symptom-specific in the modern sense: it was given to “nourish and move the blood” in conditions marked by pallor, fatigue, cold extremities, scanty or painful menstruation, and slow recovery after childbirth or illness. Crucially, it was almost never given alone. It appears as the lead root in Danggui Buxue Tang, paired five-to-one with astragalus, and as the named herb in Danggui Shaoyao San, Danggui Sini Decoction, and Siwu Tang. Different processing methods — raw, wine-fried, dry-fried, charred — were understood to shift its actions between moving blood, supplementing blood, and stopping bleeding.

Interest from outside East Asia followed a different logic. Western importers reframed the root as “female ginseng” and as a botanical alternative to hormone therapy, then tested it the way a drug is tested: one herb, one dose, one endpoint. The 1997 placebo-controlled trial of the isolated root in postmenopausal women found no estrogen-like effect and no symptom advantage, a result frequently cited as closing the question. Chinese and Korean groups continued to study the classical formulas and reported benefit for menstrual pain and blood building, so the two research traditions have largely produced parallel rather than converging literatures, and neither has definitively refuted the other.

Expected Benefits

High 🟩 🟩 🟩

No benefit of dong quai currently rests on evidence at this level; no large, low-bias randomized trial of the root or its formulas has been completed for any outcome.

Medium 🟩 🟩

Reduction of Menstrual Pain in Danggui-Based Formulas

Two independent meta-analyses of randomized controlled trials (RCTs — studies in which participants are assigned to treatment or comparison by chance) report that formulas built around dong quai outperform conventional analgesics for primary period pain. The proposed mechanism is relaxation of uterine muscle by ligustilide plus dampened cramping signals. The important caveat is attribution: the tested products are multi-herb decoctions, so the effect cannot be assigned to dong quai alone, and both pooled analyses rate the underlying trials as high risk of bias. Lee et al., Ma et al.

Magnitude: Response rate ratio 1.31 (95% confidence interval 1.06–1.63, meaning the plausible range of the true value) for a danggui formula versus analgesics across four trials; a separate pooling of eleven trials in 1,005 women also favored a danggui formula over conventional drugs.

Low 🟩

Relief of Menopausal Hot Flashes ⚠️ Conflicted

Evidence points in both directions. The astragalus–danggui pair beat placebo for mild flushes only in a six-month randomized trial, while the isolated root matched placebo in postmenopausal women and in men on hormone-blocking therapy. Haines et al., Hirata et al., Al-Bareeq et al.

Magnitude: Over six months the herb pair cut mild flushes from 18.9 to 8.6 per month versus 26.0 to 12.4 on placebo, with no advantage for moderate or severe flushes; the isolated root produced no separation from placebo.

Improvement of Red Cell Measures in Anemia

Pooled trials of the astragalus–danggui pair raised red cell count and hematocrit in kidney-related anemia beyond standard care; the polysaccharide fraction sped hemoglobin recovery in bled mice. Trial quality is poor, and the effect belongs to the pair, not the root. Zhao et al., Liu et al., Ren et al.

Magnitude: Across seven trials in 460 patients the herb pair added to standard care beat standard care alone on red blood cell count (weighted mean difference 0.49, meaning the pooled average gap between the treated and untreated groups) and hematocrit (1.92 percentage points); hemoglobin improved only in the subgroup using the classical 5:1 astragalus-to-danggui ratio.

Adjunctive Improvement in Fibrotic Lung Disease

Pooled trials of the astragalus–danggui pair added to standard care in scarred lung tissue report better breathing tests, longer walking distance and fewer adverse reactions. All trials are small, single-country, and rated at high risk of bias. Zhang et al.

Magnitude: Direction is consistently positive on lung function and six-minute walking distance across seventeen trials, but the trials report a composite “total effective rate” that does not convert to a standard effect size, so the literature provides no transferable outcome figure.

Speculative 🟨

Protection of Brain Tissue During Reduced Blood Flow

Pooled animal studies of ligustilide show smaller areas of stroke damage and better neurological scores through antioxidant and anti-inflammatory routes. No controlled human study exists; the basis is entirely preclinical. An et al.

Preservation of Bone Density After Estrogen Decline

Danggui Buxue Tang protected bone in ovariectomized rodents, alone and alongside standard bone drugs. No controlled human bone-density data exist, so the basis is mechanistic and animal only. Zhou et al.

Support of Blood Vessel Lining Function

The root’s polysaccharide and volatile oil fractions increased nitric oxide output from cultured vessel-lining cells and reduced oxidative damage to them. Basis is laboratory-only; no human vascular endpoint has been measured. Chen et al.

Benefit-Modifying Factors

  • Genetic variation: No polymorphism has been shown to alter the herb’s benefit. Variants in the liver enzymes that clear its coumarins and ferulic acid are plausible modifiers of exposure, but no pharmacogenetic study of dong quai response has been published.

  • Baseline estrogen status: The estrogen-related effects that laboratory work suggests would matter most where circulating estrogen is low, as after menopause. Women with intact ovarian function have far less room for a weak plant estrogen to register any measurable change.

  • Baseline iron and hemoglobin: The blood-building claim presumes a deficit to correct. Those with normal hemoglobin and ferritin (the body’s iron storage protein) have no headroom; the animal data derive from acute blood loss, not from iron-replete states.

  • Sex: Nearly all clinical data come from women. The one randomized trial in men, testing hot flashes during hormone-blocking cancer therapy, was null, and case reports of breast tissue growth in men suggest a different risk-benefit balance.

  • Pre-existing conditions: Painful menstruation, cold extremities, and post-illness fatigue are the traditional targets and the settings with the most supportive data. Absent those, no clinical endpoint has been shown to improve.

  • Age: Older adults are more likely to take anticoagulants, antiplatelets, and multiple prescriptions, which shifts the balance away from benefit. Age itself has not been shown to alter the herb’s effects independently of medication burden.

  • Formula versus single herb: The positive pooled data come from multi-herb decoctions. Taking the isolated root reproduces the preparation that failed in Western trials, not the preparation that produced the meta-analytic signal.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk of dong quai currently rests on evidence at this level; no adverse outcome has been established by adequately powered controlled trials.

Medium 🟥 🟥

Potentiation of Anticoagulant and Antiplatelet Medication ⚠️ Conflicted

The root contains natural coumarins and ferulic acid, both of which discourage clotting, and a documented case describes a large rise in clotting-time measures in a woman stable on warfarin. An animal study found the interaction acts on warfarin’s effect rather than its blood levels. Against this, a randomized trial in healthy volunteers found no meaningful change in platelet or clotting function, alone or with aspirin. The conflict is unresolved, and the consequence of being wrong is bleeding. Page & Lawrence, Lo et al., Fung et al.

Magnitude: A documented case showed prothrombin time (a clotting test) and the international normalized ratio (INR, a standardized version of that test) more than doubling after four weeks of concurrent use; against this, a trial found reduced platelet clumping in 2 of 24 volunteers and no change in clotting times.

Stimulation of Estrogen-Sensitive Tissue

A water extract of the root increased growth of breast cancer cell lines in culture, and did so whether or not the cells carried estrogen receptors, implying more than one growth-promoting route. In ovariectomized rats the extract stimulated the womb lining and vaginal tissue and altered cycling in intact animals. A case report describes breast tissue growth in a man taking a processed dong quai preparation. Human incidence is unknown, and the one controlled human trial found no womb lining change. Lau et al., Circosta et al., Goh & Loh

Magnitude: The extract raised proliferation of both estrogen-receptor-positive and estrogen-receptor-negative breast cancer cell lines in a dose-dependent way, and altered the estrous cycle (the rodent reproductive cycle) in 67% of intact rats; no human incidence figure exists.

Low 🟥

Photosensitivity and Skin Reactions

Angelica roots carry furanocoumarins — psoralen-type molecules that make skin react abnormally to ultraviolet light. Reports for dong quai specifically are isolated rather than systematic, but the chemistry is shared with well-documented phototoxic relatives. Li et al.

Magnitude: Not quantified in available studies. No controlled trial has measured phototoxic reaction rates for dong quai; the concern rests on constituent chemistry shared with other Angelica species and on scattered case descriptions.

Digestive Upset and Loose Stools

Bloating, belching, and loosened stools are the most commonly described complaints, consistent with the root’s oil content and its traditional use as a mild bowel-moving agent. Controlled trials and a regulatory safety assessment report no serious adverse events. Haines et al., EFSA FEEDAP Panel

Magnitude: The direction is toward mild, dose-related digestive complaints concentrated at the upper end of decoction dosing; controlled trials record no serious adverse events and report no incidence figure for these symptoms.

Contamination and Species Substitution

Commercial dong quai has been recalled for elevated lead and cadmium, a hazard common to root crops grown in contaminated soil. Analytical work separately shows that three different Angelica species circulate under overlapping trade names, so a product may not contain the species its label implies. Ahn et al.

Magnitude: Not quantified in available studies. Contamination and substitution rates are known only from individual recall actions and small analytical surveys rather than systematic market sampling, so no prevalence figure exists.

Speculative 🟨

Interference with Hormone-Blocking Cancer Therapy

If the root activates estrogen receptors at human doses, it could work against tamoxifen or aromatase inhibitors (estrogen-blocking drugs). The basis is mechanistic extrapolation from cell work; no clinical interaction has been reported.

Long-Term Coumarin Exposure and Cell Damage

Some root coumarins have been described as potentially carcinogenic in isolated laboratory conditions. The basis is mechanistic only, with no long-term human exposure data and no cancer signal in traditional-use populations.

Risk-Modifying Factors

  • Clotting-related gene variants: People carrying reduced-function CYP2C9 or VKORC1 variants (genes governing warfarin clearance and its target enzyme) already need lower warfarin doses; adding a clotting-modifying herb compounds an unstable baseline.

  • Baseline INR and platelet function: An INR already drifting near the top of its target range, or existing low platelet counts, leaves no margin should the interaction prove real in a given individual.

  • Sex: Men face an added, sex-specific concern — the case literature on breast tissue growth is exclusively male, and the single male efficacy trial found no offsetting benefit.

  • Pre-existing conditions: Hormone-sensitive cancers, endometriosis, uterine fibroids, active bleeding disorders, and scheduled surgery all shift the balance sharply toward harm.

  • Age: Older adults carry more anticoagulant and antiplatelet prescriptions and thinner, more sun-damaged skin, raising both the bleeding and the photosensitivity concerns without any corresponding gain in expected benefit.

Key Interactions & Contraindications

  • Warfarin (a prescription anticoagulant — a drug that slows blood clotting): Caution bordering on avoidance. A documented case showed clotting time more than doubling. Mitigation: weekly INR checks for one month after starting or stopping.

  • Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran): Caution. No direct data, but additive clot inhibition is plausible and no routine laboratory test catches drift early. Mitigation: avoidance is the only reliable option.

  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor — drugs that stop platelets clumping): Caution. A randomized trial found no added platelet inhibition with aspirin, but rat work suggests altered clopidogrel handling. Mitigation: monitoring for bruising and gum bleeding.

  • Over-the-counter analgesics (painkillers such as ibuprofen, naproxen, high-dose aspirin): Caution. These already impair platelet function and irritate stomach lining; adding a clot-modifying root raises gastrointestinal bleeding risk. Mitigation: avoidance of routine concurrent use.

  • Tamoxifen and aromatase inhibitors (anastrozole, letrozole — drugs that block estrogen action or production): Absolute contraindication in practice. Cell work shows the extract stimulates breast cancer cell growth. Mitigation: none; the therapeutic goal and the herb’s activity are directly opposed.

  • Supplements with additive clot-inhibiting effects (fish oil, garlic, ginkgo, high-dose vitamin E, nattokinase, curcumin): Caution. Each modestly reduces platelet clumping. Mitigation: no stacking; where already combined, all are stopped a week before any procedure.

  • Estrogenic botanicals (red clover, black cohosh, soy isoflavones, hops): Caution. Overlapping receptor activity makes the combined hormonal signal unpredictable. Mitigation: one at a time, so that any effect can be attributed to a single agent.

  • Photosensitizing drugs (doxycycline, amiodarone, thiazide diuretics, retinoids — medicines that make skin burn more easily): Caution. Furanocoumarins add to drug-induced light sensitivity, producing exaggerated sunburn. Mitigation: increased sun protection, or separation of the two.

  • Other interventions: Caution with therapeutic ultraviolet light therapy and with cosmetic laser or peel procedures, where furanocoumarin exposure can worsen post-procedure pigmentation and burning. Mitigation: stopping the root two weeks before any light-based or resurfacing procedure.

Populations who should avoid Dong Quai:

  • Pregnancy at any stage, and breastfeeding — the root is traditionally used to move blood and stimulate the uterus.
  • Estrogen-receptor-positive breast, endometrial (womb lining), or ovarian cancer, whether active or in remission.
  • Anyone within 14 days of planned surgery, dental extraction, or spinal or epidural injection.
  • Inherited or acquired bleeding disorders, including hemophilia, von Willebrand disease, and platelet counts below 100 × 10⁹/L.
  • Active peptic ulcer disease (stomach or duodenal ulcers) or gastrointestinal bleeding within the past 90 days.
  • Severe liver impairment (Child-Pugh Class C), given reliance on hepatic clearance of the root’s constituents.

Risk Mitigation Strategies

  • Fourteen-day pre-procedure stop: Discontinuing two weeks before surgery, dental work, or injections covers platelet turnover and removes the theoretical bleeding contribution during and after the procedure.

  • Weekly INR checks around any change: For anyone on warfarin who still uses the root, weekly INR for four weeks after starting or stopping catches the interaction described in the case literature.

  • Single-variable introduction: Starting dong quai alone, with no other new supplement for four weeks, allows bruising, digestive upset, or breast tenderness to be attributed rather than guessed at.

  • Daily sun protection during use: Broad-spectrum sunscreen and covered forearms address the furanocoumarin photosensitivity concern, which is most likely to appear as an exaggerated burn after ordinary sun exposure.

  • Third-party tested product only: Choosing a certificate-backed product with heavy metal testing addresses the documented lead and cadmium recall and the species-substitution problem in the trade.

  • Hard stop for hormone-sensitive history: Anyone with an estrogen-receptor-positive cancer history simply does not use it, which removes the tissue-proliferation risk that cell work identifies.

  • Three-month duration cap with review: Reassessment at 12 weeks prevents indefinite exposure to a botanical whose long-term coumarin safety has never been studied in humans.

Therapeutic Protocol

  • Classical decoction dose: Practitioners of Chinese herbal medicine typically use 6–12 g of dried root per day, simmered in water with companion herbs, rarely alone. This is the dose behind the pooled menstrual pain data.

  • Western capsule dose: Commercial monopreparations commonly supply 500–2,000 mg of powdered root or a 4:1 to 10:1 extract, taken in divided doses. This is the format that failed the placebo-controlled menopause trial.

  • Trial-replicating dose: The 1997 postmenopausal trial used 4.5 g/day of root for 24 weeks; the astragalus–danggui menopause trial used the classical 5:1 astragalus-to-danggui ratio for six months.

  • Competing approaches: The Chinese herbal tradition treats the root as one component of a pattern-matched formula. The Western supplement model treats it as a standalone botanical. Neither is the default here; they rest on different evidence bases.

  • Attribution of approaches: The formula approach traces to the Shennong Bencao Jing and to Li Dongyuan’s thirteenth-century Danggui Buxue Tang. The single-herb approach originates with Western supplement marketing, not with a named clinic or investigator.

  • Best time of day: Traditionally taken warm, 30 minutes after morning and evening meals. Food reduces the belching and reflux that the volatile oil can cause; no circadian advantage has been demonstrated.

  • Half-life and dosing frequency: Ligustilide clears within tens of minutes and ferulic acid within a few hours in animal work, which argues for split dosing twice or three times daily rather than a single daily dose.

  • Split versus single dose: Divided dosing is standard in both traditions and is the pharmacologically defensible choice given the short residence time of the two absorbed constituent classes.

  • Genetic considerations: Reduced-function CYP2C9 and VKORC1 variants matter only through the warfarin interaction. No pharmacogenetic variant has been shown to alter dong quai response itself.

  • Sex-based differences: Protocols are derived almost entirely from female populations. The single male trial used 500 mg once daily for three months and found no benefit; no male-specific protocol is established.

  • Age considerations: No age-adjusted dosing exists. For adults past 65, the practical adjustment is a lower starting dose and a review of every anticoagulant, antiplatelet, and photosensitizing prescription first.

  • Baseline biomarkers influencing response: Low hemoglobin or ferritin defines the population in which the blood-building claim could plausibly register; normal values predict no measurable hematologic change.

  • Pre-existing conditions influencing response: Painful menstruation and cold-extremity presentations are the traditional responders. Hormone-sensitive disease and anticoagulant use are not dose adjustments but reasons not to proceed.

Discontinuation & Cycling

  • Not a lifelong intervention: No evidence supports indefinite use. Traditional practice ties the root to a pattern that resolves, and long-term human safety data do not exist beyond six months.

  • Withdrawal effects: None have been documented. The root has no known dependence, receptor downregulation, or rebound phenomenon; the trials that stopped it reported no discontinuation symptoms.

  • Tapering: No taper is required. The short residence time of its absorbed constituents means abrupt cessation carries no pharmacological penalty.

  • Cycling for efficacy: No tolerance has been demonstrated, so cycling is not needed to preserve effect. Cycling is instead reasonable as an exposure-limiting measure given the absent long-term safety data.

  • Practical cycling pattern: For cyclical menstrual pain the traditional pattern doses only in the second half of the cycle and the first days of bleeding, limiting exposure to roughly a third of each month.

  • Mandatory stop points: Stop points are 14 days before surgery, any unexplained bruising or bleeding, the start of an anticoagulant, and pregnancy or a plan to conceive.

Sourcing and Quality

  • Species verification: A label naming Angelica sinensis is the minimum specification. Angelica gigas and Angelica acutiloba circulate under overlapping trade names with different chemistry, and even reference sites conflate them.

  • Heavy metal testing: Root crops concentrate soil contaminants, and a US recall named lead and cadmium in a dong quai product. A certificate of analysis covering lead, cadmium, arsenic, and mercury is the relevant check.

  • Marker standardization: Better extracts state ferulic acid content (commonly 0.05–0.1% in raw root) or ligustilide content. An extract ratio alone, such as 4:1, says nothing about the active fractions present.

  • Ligustilide instability: The volatile phthalides degrade with heat, light, and time. Opaque containers, recent manufacture dates, and cool storage preserve them; sun-bleached or odorless material has lost its oil fraction.

  • Third-party certification: NSF, USP (United States Pharmacopeia), and Informed Choice certification marks verify identity and contaminant limits independently of the manufacturer’s own claims.

  • Processing form: Traditional pharmacies distinguish raw, wine-fried, and charred root, which are held to differ in action. Western capsules almost never state which processing, if any, was used.

  • Reputable channels: Established herbal pharmacies such as Nuherbs and Spring Wind, and Good Manufacturing Practice supplement brands with published contaminant testing, are lower-risk than unbranded bulk root or online marketplace listings.

Practical Considerations

  • Time to effect: For menstrual pain, the pooled trials dosed across one to three menstrual cycles before assessing response. For menopausal symptoms, the controlled trials ran 24 weeks and still found little separation from placebo.

  • Common pitfall — taking it alone: The evidence favoring dong quai comes from multi-herb formulas; the evidence against it comes from the isolated root. Buying a single-ingredient capsule reproduces the failing arm.

  • Common pitfall — ignoring the medication list: Users often disclose prescriptions but not supplements. The bleeding concern only materializes in combination, so an undisclosed anticoagulant is the main route to harm.

  • Common pitfall — expecting hormone replacement: The root is not a hormone and has not matched estrogen therapy on any endpoint. Framing it as a hormone substitute leads to abandoning effective treatment.

  • Regulatory status: In the United States it is a dietary supplement under DSHEA (the 1994 law governing supplements), so no pre-market efficacy or purity review applies. It is not an approved drug in the US, EU, or UK.

  • Cost and payer incentives: Roughly $10–25 monthly, paid out of pocket, whereas generic hormone therapy is cheap and reimbursed. Insurers and national health systems therefore have no financial motive to favor the botanical or fund trials of it — a structural source of bias.

Interaction with Foundational Habits

  • Sleep: No direct interaction is established. An indirect effect is plausible where night sweats are reduced, though the controlled data on that reduction are weak. Evening dosing has not been shown to disturb or improve sleep architecture.

  • Nutrition: Direct interaction with iron status is plausible and potentiating: the blood-building claim presumes adequate iron, folate and vitamin B12 supply. Food blunts the reflux the volatile oil can cause, and grapefruit shares the same CYP-inhibiting behavior, making that pairing unpredictable.

  • Exercise: One direct, potentiating signal exists: a small randomized trial in male recreational runners found the astragalus–danggui pair shortened finish times and suppressed the iron-blocking hormone hepcidin after a hard run. It is a single 36-participant study; timing relative to workouts is unstudied.

  • Stress management: No direct effect on cortisol or the stress axis has been shown in humans. Any indirect benefit would run through reduced pain or fewer hot flash episodes rather than through a stress-response mechanism of its own.

Monitoring Protocol & Defining Success

Before starting, a short baseline panel establishes the two things that matter: whether there is a blood deficit for the herb to address, and whether clotting has any margin to give. A complete blood count with hemoglobin and platelets, ferritin, a clotting panel, and liver enzymes cover this, with estradiol added where menopausal symptoms are the reason for use. For anyone on an anticoagulant, a documented, stable pre-treatment value precedes the first dose.

Ongoing monitoring is light for most users and intensive for a minority. Those not on clot-modifying drugs need repeat labs only at 12 weeks and then every 6–12 months. Anyone on warfarin needs weekly INR for the first four weeks after starting or stopping, then monthly. Symptom tracking runs continuously from baseline, since the meaningful endpoints here are subjective.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin 13.5–15.0 g/dL (women); 14.5–16.0 g/dL (men) Tests the blood-building claim directly Conventional labs flag only below 12.0/13.5 g/dL; the functional target is higher. Best drawn hydrated, since dehydration falsely raises it
Ferritin 50–100 ng/mL (women); 50–150 ng/mL (men) Iron stores must be adequate for any red-cell response Rises with inflammation, so it is read alongside hs-CRP (high-sensitivity C-reactive protein, an inflammation marker). Conventional range starts at 15 ng/mL, far below the functional floor
INR (international normalized ratio) 0.9–1.1 if not anticoagulated; the individually prescribed target if on warfarin Detects the documented warfarin interaction Weekly for four weeks after starting or stopping, then monthly. Same laboratory each time, as reagent differences shift results
Platelet count 200–350 × 10⁹/L Establishes bleeding margin before adding a clot-modifying botanical Conventional range extends down to 150 × 10⁹/L; below 150 the herb is not appropriate. No fasting required
ALT Under 20 U/L (women); under 25 U/L (men) Confirms liver capacity to clear the root’s coumarins ALT stands for alanine aminotransferase, a liver enzyme. Conventional upper limits near 40 U/L are far above the functional target. Strenuous exercise in the prior 48 hours inflates it
hs-CRP Under 1.0 mg/L Baseline inflammation, and the correction factor for reading ferritin Fasting draw, away from any acute infection, which transiently multiplies the value
Estradiol No established target for dong quai users; track change from the individual’s own baseline Detects any real hormonal effect where laboratory work predicts one Only informative where menopausal symptoms are the reason for use. In cycling women, the same cycle day each time

Qualitative markers to track alongside the labs:

  • Menstrual pain severity, recorded per cycle on a 0–10 scale rather than from memory
  • Hot flash frequency and severity, logged daily rather than estimated weekly
  • Unexplained bruising, gum bleeding, or prolonged bleeding from small cuts
  • Skin reactions after ordinary sun exposure
  • Digestive comfort — bloating, belching, stool consistency
  • Breast tenderness or, in men, breast tissue changes
  • Energy on waking and cold tolerance in hands and feet

Success is a clear, logged improvement in the specific symptom that prompted use within 12 weeks, with no bleeding signal and no hormonal symptom. Absence of that improvement at 12 weeks is a reason to stop rather than to escalate the dose.

Emerging Research

  • Stroke recovery formula in phase 2/3 testing: NCT05046106 plans 540 patients on a four-herb extract containing Angelica sinensis, dosed twice daily for 24 weeks, with the modified Rankin disability scale as primary endpoint — the largest controlled test of a danggui-containing product yet designed.

  • Sarcopenia trial pairing the herb with resistance training: NCT07321535 is a 106-participant, placebo-controlled trial giving 6 g/day of Angelica sinensis root within a formula alongside elastic-band training for sarcopenia (age-related muscle loss), with a physical performance battery as primary endpoint.

  • Menstrual pain formula under prospective test: NCT06730282 will enroll 200 women to test a danggui-based formula in primary period pain, addressing the main criticism of the existing meta-analyses — that their component trials carry high risk of bias.

  • Exposure realism could weaken the case: Song et al., 2026 argue that many laboratory concentrations exceed what oral dosing can plausibly achieve in blood, and that most clinical signals derive from multi-herb formulas — a line of work that, if pursued, would narrow rather than broaden the claims.

  • Hormonal safety remains an open question: Lau et al., 2005 showed cell-line proliferation independent of estrogen receptors, a finding never followed up in humans. Any clinical study of hormone-sensitive populations could substantially strengthen or undermine current cautions.

  • Polysaccharide standardization may decide the blood-building claim: Ren et al., 2024 catalogue how structurally heterogeneous the active polysaccharides are, which is why animal hematologic results have not reproduced consistently across preparations.

Conclusion

Dong quai is a root with a two-thousand-year record of use and a thin, divided modern evidence base. The clearest signal is for menstrual pain, where pooled trials of formulas built around the root beat standard painkillers — but those formulas contain several herbs, the trials were poorly conducted, and almost all were run by institutions whose standing depends on favorable results. For menopausal symptoms, the picture is close to the opposite: the root taken alone performed no better than an inactive placebo when tested on its own, and the paired-herb version helped only the mildest flushes. The blood-building reputation does have some human support, but only from small, poorly conducted trials of the root paired with astragalus.

The risks are modest in probability and serious in consequence. The root carries compounds that slow clotting and compounds that faintly imitate estrogen. Whether either matters at human doses is unsettled — the available human evidence points in opposite directions on bleeding — but the settings where being wrong is costly are easy to name: anyone on blood thinners, anyone facing surgery, anyone with a hormone-driven cancer history, anyone pregnant.

What remains is a low-cost botanical with a narrow plausible use, weak and conflicted support, and a handful of situations where it is clearly unsuitable. The evidence does not settle the question in either direction, and nothing in the current literature closes it.

Top - Benefits - Risks - Protocol